Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Insulin Resistance Intervention After Stroke Trial (IRIS)

This study has been completed.
National Institute of Neurological Disorders and Stroke (NINDS)
Takeda Pharmaceuticals North America, Inc.
Information provided by (Responsible Party):
Yale University Identifier:
First received: September 20, 2004
Last updated: January 6, 2016
Last verified: January 2016